Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Ryo Iwamura"'
Autor:
Masashi Kumon, Masahiro Fuwa, Atsushi Shimazaki, Noriko Odani-Kawabata, Ryo Iwamura, Kenji Yoneda, Masatomo Kato
Publikováno v:
PLoS ONE, Vol 18, Iss 1 (2023)
Omidenepag isopropyl (OMDI) is an intraocular pressure (IOP)-lowering drug used to treat glaucoma. The active form of OMDI, omidenepag (OMD), lowers elevated IOP, the main risk factor for glaucoma, by increasing the aqueous humor outflow; however, a
Externí odkaz:
https://doaj.org/article/0d87df5d59dc4d78be06afa82e38851b
Autor:
Noriko Odani-Kawabata, Ryo Iwamura, Takazumi Taniguchi, Tomoko Kirihara, Atsushi Shimazaki, Masahiro Fuwa, Kenji Morishima, Kenji Yoneda, Naveed Shams, Masatomo Kato
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 37:223-229
Purpose: To investigate the intraocular pressure (IOP)-lowering effects of omidenepag isopropyl (OMDI), a potent and highly selective prostanoid EP2 receptor agonist, as a potential first-line ocul...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a06ce19eed1bf26589d524e14b80da21
https://doi.org/10.1089/jop.2020.0071
https://doi.org/10.1089/jop.2020.0071
Autor:
Yasuko Yamamoto, Naveed K Shams, Tomoaki Inazumi, Yukihiko Sugimoto, Takazumi Taniguchi, Ryo Iwamura, Kenji Yoneda, Takeshi Matsugi, Noriko Odani-Kawabata
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics
Purpose: We aimed at comparing the effects of omidenepag (OMD) with those of prostaglandin F (FP) receptor agonists (FP agonists) on adipogenesis in mouse 3T3-L1 cells. Methods: To evaluate the agonistic activities of OMD against the mouse EP2 (mEP2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e0840fb5ebe9992ea1bb8a9a4fc14fb
http://europepmc.org/articles/PMC7175626
http://europepmc.org/articles/PMC7175626
Publikováno v:
Molecular Imaging and Biology. 21:825-834
Lymph node (LN) metastasis is detected prior to distant metastasis in many types of cancer. Detecting early stage LN metastasis can improve treatment outcomes. However, there are few clinical imaging modalities capable of diagnosing metastatic LNs of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1935c52deec6b287ab3cebd4f75847db
https://doi.org/10.1007/s11307-018-01303-4
https://doi.org/10.1007/s11307-018-01303-4
Autor:
Naveed Shams, Ryo Iwamura, Yoshihiko Esaki, Takahisa Noto, Hitomi Kamio, Kenji Yoneda, Hidetoshi Mano, Noriko Odani-Kawabata, Osamu Katsuta, Kenji Morishima
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics
Purpose: The present study investigated the effects of the antiglaucoma agent and selective E2 receptor agonist omidenepag isopropyl (OMDI) on eyelash growth in comparison with a prostaglandin analog (prostamide receptor agonist) in mice. Methods: Fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266a2abae70fd228b7709285513f7b57
https://pubmed.ncbi.nlm.nih.gov/32412835
https://pubmed.ncbi.nlm.nih.gov/32412835
Autor:
Kenji Yoneda, Shan Fan, Carol B. Toris, Masaki Ichikawa, Masahiro Fuwa, Ryo Iwamura, Jin-Zhong Zhang, Takeshi Matsugi, Naveed K Shams, Noriko Odani-Kawabata, Takazumi Taniguchi
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 34:531-537
To investigate the mechanism of the intraocular pressure (IOP)-lowering effect of a novel selective prostaglandin E2 receptor 2 (EP2) receptor agonist, omidenepag isopropyl (OMDI).The effect of OMDI on IOP and aqueous humor dynamics was evaluated in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7af79a7095b0c5229d6e5c385c6c4147
https://doi.org/10.1089/jop.2017.0146
https://doi.org/10.1089/jop.2017.0146
A Novel Non‐Prostaglandin EP2‐Receptor Agonist for Glaucoma Treatment: Omidenepag Isopropyl (DE‐117)
Autor:
Ryo Iwamura, Tomoko Kirihara, Helen Lu, Noriko Odani-Kawabata, Kenji Yoneda, Sharif Najam A, Naveed Shams
Publikováno v:
The FASEB Journal. 34:1-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49f5a9fbf034674d53f84461907be240
https://doi.org/10.1096/fasebj.2020.34.s1.08817
https://doi.org/10.1096/fasebj.2020.34.s1.08817
Autor:
Eiji Okanari, Tomoko Kirihara, Kenji Yoneda, Ryo Iwamura, Naveed K Shams, Noriko Odani-Kawabata, Masayuki Tanaka
Publikováno v:
Journal of medicinal chemistry. 61(15)
EP2 receptor agonists are expected to be effective ocular hypotensive agents; however, it has been suggested that agonism to other EP receptor subtypes may lead to undesirable effects. Through medicinal chemistry efforts, we identified a scaffold bea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f458e261a47f1077ac8e3431a66d45
https://pubmed.ncbi.nlm.nih.gov/29995405
https://pubmed.ncbi.nlm.nih.gov/29995405
Autor:
Takazumi Taniguchi, Noriko Odani-Kawabata, Tomoko Kirihara, Atsushi Shimazaki, Kenzo Yamamura, Kenji Yoneda, Takeshi Matsugi, Jin-Zhong Zhang, Naveed K Shams, Ryo Iwamura
Publikováno v:
Investigative Opthalmology & Visual Science. 59:145
Purpose The objective of this study was to investigate the pharmacologic characteristics of omidenepag isopropyl (OMDI), a compound developed as a novel intraocular pressure (IOP)-lowering agent, with better IOP control and fewer side effects than ot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b73ea39ab3a1504a8f4aeb4389c141
https://doi.org/10.1167/iovs.17-22745
https://doi.org/10.1167/iovs.17-22745
Publikováno v:
The Proceedings of the Bioengineering Conference Annual Meeting of BED/JSME. :2B26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffe0d39a29c6956acfa7d8b7c9a94d51
https://doi.org/10.1299/jsmebio.2017.29.2b26
https://doi.org/10.1299/jsmebio.2017.29.2b26